Unknown

Dataset Information

0

Prospective longitudinal quality of life and survival outcomes in patients with advanced infiltrative hepatocellular carcinoma and portal vein thrombosis treated with Yttrium-90 radioembolization.


ABSTRACT: BACKGROUND:To determine the effect of Yttrium-90 (Y90) radioembolization on health-related quality of life (HRQOL) and its effect on overall survival advanced, unresectable infiltrative hepatocellular carcinoma (HCC) patients with concurrent portal vein thrombosis (PVT). METHODS:Consecutive patients with unresectable infiltrative HCC and PVT were recruited. The Short-Form 36 (SF-36) questionnaire was used to assess HRQOL for consecutive patients treated with glass-based Y90 based on a prospective phase II trial. MR imaging was used to determine tumor progression every 3 months post-treatment. Overall survival (OS) from treatment and time to progression (TTP) was analyzed using Kaplan-Meier estimation and log-rank test. RESULTS:Thirty patients were treated and followed for 17.4 months; physical and mental component summary scores (PCS & MCS) remained unchanged at one, three, and six months. While no difference was observed in baseline SF-36 scores for patients with prolonged TTP (?4 months) and OS (? 6 months), corresponding 1-month PCS were significantly higher than those with TTP?

SUBMITTER: Xing M 

PROVIDER: S-EPMC5766991 | biostudies-literature | 2018 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Prospective longitudinal quality of life and survival outcomes in patients with advanced infiltrative hepatocellular carcinoma and portal vein thrombosis treated with Yttrium-90 radioembolization.

Xing Minzhi M   Kokabi Nima N   Camacho Juan C JC   Kim Hyun S HS  

BMC cancer 20180112 1


<h4>Background</h4>To determine the effect of Yttrium-90 (Y90) radioembolization on health-related quality of life (HRQOL) and its effect on overall survival advanced, unresectable infiltrative hepatocellular carcinoma (HCC) patients with concurrent portal vein thrombosis (PVT).<h4>Methods</h4>Consecutive patients with unresectable infiltrative HCC and PVT were recruited. The Short-Form 36 (SF-36) questionnaire was used to assess HRQOL for consecutive patients treated with glass-based Y90 based  ...[more]

Similar Datasets

| S-EPMC6541348 | biostudies-literature
| S-EPMC10035716 | biostudies-literature
| S-EPMC4439788 | biostudies-literature
| S-EPMC7655630 | biostudies-literature
| S-EPMC4404379 | biostudies-literature
| S-EPMC8497088 | biostudies-literature
| S-EPMC4882351 | biostudies-other
| S-EPMC4858257 | biostudies-literature
| S-EPMC5081020 | biostudies-literature
| S-EPMC3527660 | biostudies-literature